2025 Judges | Finals

Angela Hwang, CEO-Partner at Flagship Pioneering and CEO at Metaphore Biotechnologies

Angela Hwang joined Flagship Pioneering in 2025 as CEO-Partner and CEO of Metaphore Biotechnologies. Angela brings nearly three decades of experience at Pfizer where she held various leadership roles, including most recently as a member of Pfizer’s executive leadership team, serving as Chief Commercial Officer and President of the Global Biopharmaceuticals Business. During her tenure, Angela’s teams brought nearly 600 critical therapies in oncology, internal medicine, rare diseases, inflammation and immunology, vaccines and hospital injectables to patients across 185 countries. She has led many groundbreaking product launches during her career, including the world’s first COVID-19 vaccine and oral antiviral treatment, and executed dozens of business development deals to grow and expand Pfizer’s portfolio.

Angela currently serves on the Board of Directors of UPS. She is also on Cornell’s Johnson Graduate School of Management’s Advisory Committee and is a board member of Connecticut Innovations, Connecticut’s state venture capital fund. Consistently recognized for her leadership, she has been ranked among the world’s top leaders in healthcare and business. In 2024, Angela was selected by CNBC as a Changemaker in Business. In 2023, she was recognized as a Ascend A-list Honoree for her professional achievements as an Asian American leader. Fortune named her as one of The Most Powerful Women in Business four years in a row from 2020 to 2023. Cornell University named her a Robert S. Hatfield Economic Fellow in 2022. In 2021, she received The President’s Award from the National Diversity Council and was also named an A100 Honoree which recognizes the most impactful AAPI leaders. Angela received a BS in Microbiology from the University of Cape Town and an MBA from Cornell University.

Deborah Di Sanzo, President of Best Buy Health

Deborah Di Sanzo is president of Best Buy Health for Best Buy Co. Inc. She is responsible for the company’s health technology business.

Best Buy Health enables care at home for everyone across the continuum of care based on Best Buy’s core competencies. Together, our integrated technology, personalized caring centers and technical services, logistics, supply chain, and omnichannel experiences enable consumers to develop meaningful connections with their caregivers, insurers, and clinicians.

Best Buy Health includes our Lively brand of connected health and personal emergency response services for the aging population, which Best Buy acquired in 2018, as well as Current Health, a leading care at home technology platform which Best Buy acquired in 2021.

Deborah is an innovative leader with more than 30 years of experience at the intersection of health care and technology. Prior to Best Buy, Deborah was the General Manager of IBM Watson Health, and prior to IBM, she was the CEO of Philips Healthcare. She teaches “AI in Health” and “Managing Information in Health Care” at the Harvard T.H. Chan School of Public Health. Deborah holds a bachelor’s degree from Merrimack College and an MBA from Babson College. She is a Harvard University Advanced Leadership Initiative Fellow and serves on the board of AstraZeneca.

Meredith Fisher, Partner at MGB Innovation Fund

Meredith Fisher is a Partner with Mass General Brigham Ventures, focusing on early-stage investments and company creation. She brings a wealth of experience from her prior role as Director of Private Investments at Bracebridge Capital, where she led investments in early-stage life science companies. Meredith’s career also includes extensive experience in business development, investing, and technical drug discovery, with key roles at Ginkgo BioWorks, PureTech Ventures, Idenix Pharmaceuticals, and Anadys Pharmaceuticals.

In addition to her professional achievements, Meredith is deeply committed to fostering innovation in the life sciences sector. She holds board positions at FireCyte, Nocion, ClarisBio, and ZielBio, and is a co-founder and board member of Violet, Brave Bio, and Mediar. She also serves as a board observer for Scorpion Therapeutics and Amolyt Pharma, further extending her influence in shaping transformative healthcare ventures.

Meredith’s academic credentials include a PhD from Harvard University, an MBA from the MIT Sloan School of Management, and an undergraduate degree from Mount Holyoke College. While at Harvard, she co-founded Harvard Graduate Women in Science and Engineering (HGWISE), demonstrating her commitment to advancing diversity and inclusion in STEM fields.

Vic Lanio, Partner at Flare Capital Partners

Vic Lanio is a Partner at Flare Capital Partners. Vic led the firm’s investments in Elektra Health, Greater Good Health, and Ounce of Care. In addition, in the past, he held Board observer roles with Aspen RxHealth, Axuall, Circulation (acquired by LogistiCare), Cohere Health, Oui Therapeutics, Tausight, Visana Health, Visitpay (acquired by R1), and Vita Health. He also has led the firm’s Flare Scholars Ventures investments in Marigold Health, Piction Health, and Ounce of Care.

Before joining Flare Capital, Vic held corporate development roles at Curaspan, which was acquired by naviHealth in 2016. After the acquisition, he transitioned to oversee product strategy in the parent company. Vic started his career in healthcare as a hospital system consultant at PwC and McKinsey & Company. He focused primarily on health system strategy within the context of the Affordable Care Act, the transition to value-based care, the revenue cycle, and clinical operations work. At McKinsey, he worked on the Objective Health team, a tech-enabled consulting model for small to mid-sized health systems. He also helped launch and served as the President and Executive Board Chair of Boston Young Healthcare Professionals, a 501(c)(3) organization aimed at providing educational, networking, and community service opportunities for young healthcare professionals in Boston.

Vic obtained his undergraduate degree from Boston College, with majors in Physics and Management with a Concentration in Finance. He also obtained his MBA from the MIT Sloan School of Management. While completing his MBA, Vic co-directed the inaugural MIT Healthcare Innovations Prize in 2016.

Jonathan NG, CEO of Iterative Health

Jonathan Ng, MBBS, is the founder and CEO of Iterative Health, a company revolutionizing gastroenterology through AI to enhance access to high-quality medical care and address disparities in healthcare outcomes. Before founding Iterative Health, Jonathan served as a Medical Officer at the Ministry of Health in Singapore, where he gained firsthand insight into the challenges of healthcare delivery. In addition to his professional achievements, Jonathan has a long-standing commitment to healthcare philanthropy. He founded and chaired Children of Cambodia, a philanthropic organization that significantly improved pediatric care in the region by raising approximately $20 million over 14 years to establish hospitals and operating theaters.

Jonathan earned his MBBS from the National University of Singapore and later pursued further education at Harvard's Kennedy School of Government and MIT's Sloan School of Management. During his time at MIT, he began exploring the potential of computer vision and AI in healthcare, inspiring him to create Iterative Health in 2017. Under his leadership, the company has developed innovative AI tools like SKOUT, which improve the accuracy and consistency of colorectal cancer detection, a critical advancement in the fight against one of the leading causes of cancer deaths globally.

Jonathan's dedication to advancing healthcare equity and using technology to address complex medical challenges has earned him recognition, including being named to the PharmaVoice 100 in 2022.

Rene Mora, Portfolio Manager at Monashee Investment Management

Dr. Rene Mora has served as Portfolio Manager at Monashee Investment Management since 2020, where he oversees healthcare investments in public and private companies. In this role, he leverages his extensive expertise in healthcare and finance to identify high-impact investment opportunities within the sector. Prior to Monashee, Dr. Mora was Chief Scientific Officer at Leerink Partners from 2000 to 2020. There, he collaborated with the Corporate Finance group on due diligence for financing transactions and mergers & acquisitions and structured proprietary research projects for corporate banking clients.

Dr. Mora's academic journey began at Brown University, followed by earning a Ph.D. in Biochemistry and an M.D. from the University of Chicago. He completed board certifications in Internal Medicine, Pulmonary Diseases, and Critical Care Medicine and held leadership roles in medicine, including as Director of the Medical Intensive Care Unit at Beth Israel Deaconess Medical Center and Associate Physician at Brigham and Women’s Hospital. He also served as an Instructor in Medicine at Harvard Medical School, publishing over 30 manuscripts in medical journals and textbooks.

Dr. Mora’s transition from medicine to finance exemplifies his ability to translate clinical expertise into strategic investment insights. He has shared his multidisciplinary experience through educational initiatives, including seminars on the intersection of research, finance, and healthcare. 

2025 SHIP Judges | Semi-Finals